Minimizing the Risk of Bleeding with NOACs in the Elderly

  title={Minimizing the Risk of Bleeding with NOACs in the Elderly},
  author={Amartya Kundu and Partha Sardar and Saurav Chatterjee and Wilbert S. Aronow and Theophilus E. Owan and John J. Ryan},
  journal={Drugs \& Aging},
Novel oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban and edoxaban have gained a lot of popularity as alternatives to warfarin for anticoagulation in various clinical settings. However, there is conflicting opinion regarding the absolute benefit of NOAC use in elderly patients. Low body mass, altered body composition of fat and muscle, renal impairment and concurrent presence of multiple comorbidities predispose elderly patients to many adverse effects with NOACs that are… 

Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword

The benefits of individual NOACs in comparison with warfarin in elderly patients are reviewed and the large number of limitations imposed by the use of vitamin K antagonists are overcome.

[Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?]

Elderly patients have the greatest benefit from NOAC along with a low renal elimination rate and they should certainly not be withheld from elderly patients who have a clear need for oral anticoagulation.

Bleeding Complications in Atrial Fibrillation Patients on Anticoagulant Therapy

Evaluated the safety of direct oral anticoagulants dabigatran, rivaroxaban and apixaban by comparing each agent with a widely used vitamin K antagonist (VKA)-acenocoumarol in terms of bleeding event rates, finding no statistically significant difference.

Elderly Bleeding Risk of Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Cohort Studies

This systematic review and meta-analysis investigates which DOAC has the lowest bleeding risk in elderly patients with nonvalvular atrial fibrillation (NVAF) and findsApixaban and dabigatran have a significantly decreased major bleeding risk compared with warfarin.

Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs

This review summarizes the literature on the safety and interactions of AADs when used with DOACs [dabigatran (a direct inhibitor of factor IIa and rivaroxaban, apixaban and edoxaban (direct inhibitors of factor Xa)] and the impact of renal and hepatic impairment.

Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture

A narrative review of the evidence to date supporting the urgent management of hip fracture in anticoagulated elderly patients and the complexity of managing the high risk of procedure‐related bleeding and, at the same time, thehigh risk of thromboembolism is discussed.

Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know

The authors provide a practical tool to assist in DOAC monitoring and recommend that pharmacists collaborate with physicians in selecting appropriate patients and tailoring patient‐specific monitoring plans.

Expert Opinion on the Use of Novel Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation for the Primary Care Setting in India: A Literature Review

This review aimed to identify the key decision points for the CPs to diagnose AF and initiate anticoagulation in patients with non-valvular AF (NVAF) and bring to the table a simplified recommendation supported by expert opinion and guidelines for stroke prevention in NVAF patients.

Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments

Hospital physicians chose anticoagulants based on patient conditions as renal function, bleeding risks, and drug interactions being the most common taken into account, but could not say which NOAC was best, and wish that future studies could compare the different NOACs, and not just compare with warfarin.

Apixaban in Elderly Patients with Atrial Fibrillation and Renal Dysfunction: Findings from A National Registry

Appropriate dose apixaban is a considerable alternative to warfarin in older adults with concurrent renal impairment for stroke prevention in the setting of AF.



Use of anticoagulants in elderly patients: practical recommendations

Assessing the benefit-risk ratio of anticoagulation is one of the most challenging issues in the individual elderly patient, patients at highest hemorrhagic risk often being those who would have the greatest benefit from anticoAGulants.

Management of Venous Thromboembolism in the Elderly

Unfractionated and low-molecular-weight heparins (LMWHs) have been shows to be safe and effective in the prophylaxis of VTE, and are now being shown to be as effective as warfarin in the initial and long-term treatment of V TE.

New oral anticoagulants in elderly patients with atrial fibrillation.

Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis

DOACs demonstrated at least equal efficacy to VKA in managing thrombotic risks in the elderly, but bleeding patterns were distinct, and dabigatran was associated with a higher risk of gastrointestinal bleeding than VKA.

Concerns About the Use of New Oral Anticoagulants for Stroke Prevention in Elderly Patients with Atrial Fibrillation

Concerns about the use of NOAC in the elderly are the high prevalence of renal insufficiency in AF patients >75 years of age, the largely unknown risk of drug–drug and drug–food interactions, the lack of easily available laboratory monitoring tests of anticoagulant activity and the absence of an antidote.

Oral Anticoagulation in Elderly Adults with Atrial Fibrillation: Integrating New Options with Old Concepts

A comprehensive PubMed‐based search of the literature published in English from 1990 through July 2012 was conducted to address the most relevant questions regarding anticoagulation in elderly adults, including fall risk, responsiveness to warfarin, physician perception of risks, and other barriers to the prescription of antICOagulants.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism.

Edoxaban versus warfarin in patients with atrial fibrillation.

Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.

Apixaban versus warfarin in patients with atrial fibrillation.

In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.

Update on Antithrombotic Therapy: New Anticoagulants

The results of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial, which compared dabigatran etexilate with warfarin for stroke prevention in patients with AF, demonstrate that the new oral anticoagULants have the potential to be more effective and safer than VKAs.